Etiketter

Summa sidvisningar

Leta i den här bloggen

onsdag 8 maj 2019

Tarkempaa tietoa SGLT2 funktiosta

haku "SGLT2"  Huom tässä en hae  SGLT2 inhibiittorista, vaan itsestään SGLT2:sta tietoa.
https://www.ncbi.nlm.nih.gov/pubmed/?term=SGLT2
Yhteensä 2136 vastausta.  Katson 20 ensimmäistä tähän ja huomaan että kaikki ovat tältä vuodelta 2019, joten asia on suuresti aktiivisti  keskiössä. En tarkemmin  kirjoita mitään kommenttia vielä. Näyttää kuitenkin siltä että munuaisen ( ainutlaatuisen  verenkierron omaavan elimen )  suhteen SGLT2 estäjästä on hyötyjä diabeteksessa.

Search results

Items: 1 to 20 of 2136

1.
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes.
[No authors listed]
JAMA. 2019 May 7;321(17):1720-1721. doi: 10.1001/jama.2019.2702. No abstract available.
PMID:
31063571
Similar articles
2.
Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases.
Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH.
Ann Intern Med. 2019 May 7. doi: 10.7326/M19-0085. [Epub ahead of print]
PMID:
31060053
Similar articles
3.
Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation.
Behnammanesh G, Durante ZE, Peyton KJ, Martinez-Lemus LA, Brown SM, Bender SB, Durante W.
Front Pharmacol. 2019 Apr 16;10:362. doi: 10.3389/fphar.2019.00362. eCollection 2019.
PMID:
31057401
Free Article
Similar articles
4.
Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis.
Wang A, Yang K, Wang T, Zhang N, Tang H, Feng X.
Diabetes Metab Res Rev. 2019 May 3:e3174. doi: 10.1002/dmrr.3174. [Epub ahead of print]
PMID:
31050384
Similar articles
5.
Acute Kidney Injury with sodium-glucose linked cotransporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials.
Gilbert RE, Thorpe KE.
Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13754. [Epub ahead of print]
PMID:
31050116
Similar articles
6.
Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation between sglt2 inhibitors and dpp4 inhibitors using a supervised machine learning algorithm (profile study): A Retrospective analysis of a japanese commercial medical database.
Zhou FL, Watada H, Tajima Y, Berthelot M, Kang D, Esnault C, Shuto Y, Maegawa H, Koya D.
Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13753. [Epub ahead of print]
PMID:
31050099
Similar articles
7.
How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol.
Hinton W, Feher MD, Munro N, de Lusignan S.
Diabetes Ther. 2019 Apr 30. doi: 10.1007/s13300-019-0620-8. [Epub ahead of print]
PMID:
31041781
Similar articles
8.
Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
Chen Z, Li G.
Clin Drug Investig. 2019 Apr 30. doi: 10.1007/s40261-019-00781-w. [Epub ahead of print] Review.
PMID:
31041606
Similar articles
9.
Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Yurista SR, Silljé HHW, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD.
Eur J Heart Fail. 2019 Apr 29. doi: 10.1002/ejhf.1473. [Epub ahead of print]
PMID:
31033127
Similar articles
10.
Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice.
Takahashi H, Nomiyama T, Terawaki Y, Horikawa T, Kawanami T, Hamaguchi Y, Tanaka T, Motonaga R, Fukuda T, Tanabe M, Yanase T.
Biochem Biophys Rep. 2019 Apr 19;18:100640. doi: 10.1016/j.bbrep.2019.100640. eCollection 2019 Jul.
PMID:
31032431
Free PMC Article
Similar articles
11.
Study on the interaction of ertugliflozin with human serum albumin in vitro by multispectroscopic methods, molecular docking, and molecular dynamics simulation.
Wang W, Gan N, Sun Q, Wu D, Gan R, Zhang M, Tang P, Li H.
Spectrochim Acta A Mol Biomol Spectrosc. 2019 Apr 18;219:83-90. doi: 10.1016/j.saa.2019.04.047. [Epub ahead of print]
PMID:
31030051
Similar articles
12.
Challenges in the Diagnosis of Euglycemic Diabetic Ketoacidosis in a Patient With Multiple Sclerosis Taking a Sodium-Glucose Cotransporter 2 Inhibitor.
Allison R, Goldstein D, Musso MW.
J Emerg Med. 2019 Apr 23. pii: S0736-4679(19)30137-4. doi: 10.1016/j.jemermed.2019.03.011. [Epub ahead of print]
PMID:
31027990
Similar articles
13.
SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018).
Pandey J, Tamrakar AK.
Expert Opin Ther Pat. 2019 Apr 26:1-16. doi: 10.1080/13543776.2019.1612879. [Epub ahead of print]
PMID:
31026402
Similar articles
14.
The protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease, and type 2 diabetes.
Miyoshi H, Kameda H, Yamashita K, Nakamura A, Kurihara Y.
J Diabetes Investig. 2019 Apr 26. doi: 10.1111/jdi.13064. [Epub ahead of print]
PMID:
31026373
Free Article
Similar articles
15.
Pharmacokinetic and Pharmacodynamic Modeling for Renal Function Dependent Urinary Glucose Excretion Effect of Ipragliflozin, a Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, Both in Healthy Subjects and Patients with Type 2 Diabetes Mellitus.
Saito M, Kaibara A, Kadokura T, Toyoshima J, Yoshida S, Kazuta K, Ueyama E.
Br J Clin Pharmacol. 2019 Apr 26. doi: 10.1111/bcp.13972. [Epub ahead of print]
PMID:
31026084
Similar articles
16.
Fournier's Gangrene and Sodium-glucose Co-transporter 2(SGLT2) Inhibitors: Our Experience.
Dass AS, Immaculate G, Bhattacharyya A.
Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):165-166. doi: 10.4103/ijem.IJEM_614_18. No abstract available.
PMID:
31016172
Free PMC Article
Similar articles
17.
Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control.
Baruah MP, Makkar BM, Ghatnatti VB, Mandal K.
Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):140-149. doi: 10.4103/ijem.IJEM_160_17. Review.
PMID:
31016169
Free PMC Article
Similar articles
18.
High Prevalence of Genital Mycotic Infections with Sodium-glucose Co-transporter 2 Inhibitors among Indian Patients with Type 2 Diabetes.
Aggarwal A, Wadhwa R, Kapoor D, Khanna R.
Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):9-13. doi: 10.4103/ijem.IJEM_244_18.
PMID:
31016146
Free PMC Article
Similar articles
19.
Assessment of the benefit-risk balance of SGLT2 inhibitors: Commentary on a new 'French paradox'.
Scheen AJ, Darmon P, Hanaire H; writing committee of the position statement by the French-Speaking Society of Diabetes (SFD).
Diabetes Metab. 2019 Apr 18. pii: S1262-3636(19)30061-8. doi: 10.1016/j.diabet.2019.04.001. [Epub ahead of print] No abstract available.
PMID:
31005757
Similar articles
20.
Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization.
Baker HE, Kiel AM, Luebbe ST, Simon BR, Earl CC, Regmi A, Roell WC, Mather KJ, Tune JD, Goodwill AG.
Basic Res Cardiol. 2019 Apr 19;114(3):25. doi: 10.1007/s00395-019-0733-2.
PMID:
31004234
Similar articles
Upplagd av kl.
Etiketter:

Inga kommentarer:

Skicka en kommentar

Prenumerera på: Kommentarer till inlägget (Atom)